Hetero launches first generic ‘ COVIFOR’ in India for Covid-19 treatment

Hetero’s generic version of Remdesivir will be marketed under the brand name ‘COVIFOR’ in India, the Pharmaceutical company said in a release here.

The drug ‘Remdesivir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease.

COVIFOR (Remdesivir) will be available in 100 mg vial (Injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner, the release said.

The product is launched under a licensing agreement with Gilead Sciences Inc to expand access to COVID-19 treatment in low and middle-income countries.

Hetero Group Chairman Dr B Partha Saradhi Reddy, said, “In the light of increasing COVID-19 cases in the country, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes."

Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country, he said we are prepared for ensuring enough stocks required to cater to the present needs.

We will continue to work closely with the government and medical community to fight against COVID-19 and this product is made indigenously in line with‘Make in India’ campaign as envisioned by the Prime Minister, he added.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs and it is globally recognised for its strengths in Research and Development, manufacturing and commercialisation of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities.